CURRICULUM VITAE - University of Maryland School of …



Curriculum VitaeMatthew Bryan Frieman, Ph.D.Associate Professor, Department of Microbiology and ImmunologyAffiliate Member, The Center for Vaccine Development and Global HealthAffiliate Member, Institute of Human VirologyThe University of Maryland School of MedicineBaltimore, MD 21201DateApril 5, 2020Contact Information655 West Baltimore St.Room 380Baltimore, MD 21201410-706-2539mfrieman@som.umaryland.eduEducation1994-1998 B.A. Biology. Washington University in St Louis, St. Louis, MOAdvisor: Dr. Craig Pikaard1998-2004 Ph.D. Johns Hopkins University School of Medicine, Baltimore MDThesis Title “Fungal Cell Wall Proteins”Thesis Advisor: Dr. Brendan CormackPost Graduate Education and Training2004- 2009 Postdoctoral Fellow, University of North Carolina at Chapel Hill, Department of Epidemiology. Advisor: Dr. Ralph BaricEmployment History2009-2015Assistant Professor (Tenure Track)University of Maryland School of MedicineDepartment of Microbiology and ImmunologyCoronavirus Pathogenesis and Host Response2015-2019Associate Professor (Tenure Track)University of Maryland School of MedicineDepartment of Microbiology and ImmunologyCoronavirus Pathogenesis and Host Response2019-PresentAssociate Professor (Tenured)University of Maryland School of MedicineDepartment of Microbiology and ImmunologyCoronavirus Pathogenesis and Host ResponseProfessional Society Memberships2006-present Member of the American Society for Virology2008-present Member of the American Society of MicrobiologyAwards and Honors1994-1997 HHMI Summer Research Fellowship to support research in the lab of Dr. Craig Pikaard (Washington Univ. in St. Louis)1995-1997 HHMI Summer Research Travel Award (Wash Univ. in St. Louis)2007 UNC-CH Post-Doctoral Award for Research Excellence 2007 ASV Post-Doctoral Travel Scholarship (UNC-CH)2010,2012Teaching Commendation for Host Defenses and Infectious Diseases (UMSOM)2014Winner, Daily Record, Innovator of the YearNominated for University of Maryland Research of the Year2015-19Teaching Commendation for Host Defenses and Infectious Diseases (UMSOM)Institutional Service2010 – 2015Virology Speaker organizer, Department of Microbiology and Immunology, Seminar Series2011 – 2018Chair, Faculty Search CommitteeDepartment of Microbiology and Immunology *responsible for reviewing applications, inviting applicants, organizing seminars2011 – presentMember, Microbiology and Immunology admissions committee(graduate student applicant interviewer from 2010-present)*responsible for reviewing graduate student applications to the Microbiology and Immunology Graduate program on a yearly basis and interviewing applicants during their visit2011 – presentCo-creator, Student Seminar Series (with Tonya Webb)*Created and helped organize seminar series for Microbiology and Immunology graduate students to present their research in progress2012 – 2016T32 Research Advisory Committee for Kurt Pipenbrink *twice annual meeting as advisor on committee2017-presentChair, Faculty Search Committee for Joint position in The Center for Vaccine Development and The Department of Microbiology and Immunology2017Co-Organizer for Passano Lecture, UMSOM.2015-2018Nathan Schnaper Summer Intern Program Admissions CommitteeLocal and National Service2007-presentReviewer for Journal of Virology (average 6x/yr)2007-presentReviewer for Virus Research (average 3x/yr)2009-presentReviewer for PLOS Pathogens (average 4x/yr)2009-presentReviewer for PLOS One (average 3x/yr)2009-presentReviewer for Emerging Infectious Diseases (average 6x/yr)2009-presentReviewer for Virology (average 4x/yr)2009-presentReviewer for Antiviral Research (average 4x/yr)2012Ad hoc reviewer for NIH Virology B Study Section2014-presentEditorial Board Journal of Virology2014–2017Chair, American Society of Virology Communications Committee 2017-presentMember, American Society of Virology Communications Committee2015-2016Editorial Board Nature Science Reports2015-presentEditorial Board, mSphere2016Participant, France-U.S. Bilateral Meeting on Dual Use Research, US Department of State2017-2018Virology Expert for Gryphon Consulting contract on Dual Use Research2018Reviewer for Congressionally Directed Medical Research Programs (CDMRP), Peer Reviewed Medical Research Program (PRMRP)Teaching Service2009-presentLecturer, Graduate School “Principles of Virology” Course10-12 Second and third year graduate students5 contact hours/yr2010-presentLecturer, University of Maryland Medical School “Host Defenses and Infectious Diseases” Course5 contact hours/yr, 120 students per year2010-presentLecturer, University of Maryland Medical School “Host Defenses and Infectious Diseases” and Small Groups section leader9 contact hours/yr, 25 students per year2010-presentLecturer, Johns Hopkins School of Medicine, “Coronavirus Biology”, Introduction to Virology Course headed by Dr. Andrew Pekocz. (yearly lecture)2012-2015Chair, Cell Signaling Section of GPLS 601 “Core Course”30 contact hours/yr as chair of section2012-presentLecturer, Cell Signaling Section of GPLS 601 “Core Course”3 Lecture hours and 30 contact hours/yr as chair of section~60 students per year2015-presentLecturer, UMSOM “Host Defenses and Infectious Diseases” and Small Groups section leader9 contact hours/yr, 25 students per year2015-presentLecturer, Global Virus Network. Virology Course. “Coronaviruses”2015 Lecturer, Johns Hopkins School of Medicine, Zika and Ebola virus Emergence.2016Lecturer, Community College of Baltimore County, Zika and Ebola virus Emergence.2016Lecturer, Infectious Disease Fellows Talk “SARS and MERS Coronaviruses”2017-presentVirology Section Head, UMSOM “Host Defenses and Infectious Diseases” 2018, 2019Lecturer, Infectious Disease Fellows Talk “SARS and MERS Coronaviruses”TraineesPost-Doctoral Fellows2012-2017Christopher Coleman PhD. (PhD from University of Sheffield, England)Research Topic, “MERS Coronavirus Therapeutics and Pathogenesis”Currently an Assistant Professor, The University of Nottingham2014-2016Jeanne Sisk, PhD. (PhD from The Johns Hopkins University)Research Topic, “Therapeutics for SARS-CoV and MERS-CoV”Currently an analyst, FDA2016-2019Kirsten Kulcsar, PhD (PhD from The Johns Hopkins University)Research Topic, “Effect of Diabetic Comorbidity on MERS-CoV Pathogenesis”Currently AAAS Fellow at The US Department of State2016-presentStuart Weston, PhD (PhD from University College London)Research Topic, “Yeast-Based Screens for Viral Protein Genetic Interactors and Anti-Viral Compounds”Graduate Students2009-2013Carly Page, PhD. GIPLS Program in Microbiology and Immunology program at UMBThesis Title: Role of Alternatively Activated Macrophages in SARS-CoV Pathogenesis.Currently: Program Manager at Johns Hopkins University 2010-2014Justin Taylor, PhD. GIPLS Program in Microbiology and Immunology program at UMBThesis Title: BST-2 restricts SARS Coronavirus and is antagonized by SARS-CoV ORF7a.Currently: Senior Scientist at Noblis2013-2017Venkataraman Thiagarajan (Raja), PhD.GIPLS Program in Microbiology and Immunology program at UMBResearch Project: Role of EGFR in SARS-CoV PathogenesisCurrently: Post-doctoral Fellow at Johns Hopkins University.2017-presentMajor Robert HauptGIPLS Program in Microbiology and Immunology program at UMBResearch Project: Adjuvant design for RSV and MERS-CoV VaccinesActive Grant/Contracts Emergent Biosystems, Inc. 02/05/20 – 08/04/20$250,000Title: n-CoVID 19 Coronavirus TestingRole: PIRegeneron02/12/20-02/11/21$448,888 direct costsTitle: Evaluation of anti-TMPRSS2 and Anti-Spike for antiviral activity against 2019-nCovRole: PIR01 AI125215-A1 (MPI: Vogel/Blanco) 07/01/17 – 08/31/22NIH/NIAID$7,278 salary only Targeting TLR signaling pathway-mediated acute lung injury Role: CollaboratorUMCP- MPower11/27/16 – 06/30/20$121,655Title: Contagious Phenotypes of Acute Respiratory Infections: Identification, Characterization, and BiomarkersRole: Sub PI (With Don Milton)Pfizer03/15/20 – 03/14/21$250,000Title: Anti-viral drug testing for SARS-CoV-2Role: PINovavax02/01/20 – 01/31/21$250,000Title: Vaccine development for SARS-CoV-2Role: PIAstrazenica03/15/20 – 03/14/21$250,000Title: Anti-viral testing for SARS-CoV-2Role: PIGates Foundation03/15/20 – 03/14/21$293,016 Title: Anti-viral development for SARS-CoV-2Role: PINIAID/CIVIC04/15/20 – 03/14/21$400,000Title: Evaluation of novel engineered Lipid A-based adjuvants with broadly protective neuraminidase antigensRole: Co-PI (With Ernst)BARDA08/01/20 – 07/31/22$520,000Title: Animal Model Development for SARS-CoV-2Role: PINIAID07/01/20 – 06/30/22R21$250,000Title: Broad Spectrum Anti-viral Compounds Targeting the SKI ComplexRole: PIDARPA04/01/20 – 03/31/21$1,500,00 Total to MFTitle: Ultra-Rapid Drug Repurposing for COVID19 Therapeutics Role: Co-PIPENDINGMRIGlobal04/01/20 – 03/31/213.6 CMTitle: Animal Model Development for SARS-CoV-2Role: SubcontractNIAID/CEIRS04/15/20 – 03/14/22$398,805Title: Therapeutic testing and animal model development for the SARS-CoV-2 Wuhan Coronavirus Role: Co-PINIAID10/01/20 – 09/30/22R21$250,000Title: Host-pathogen interactions of SARS-CoV-2 strain Wuhan-Hu-1 generated via synthetic genomics Role: Co-PI (JCVI)NIAID10/01/20 – 09/30/22R01$1,250,000 (direct to MF)Title: The role of diabetic comorbidity in MERS-CoV pathogenesisRole: PICompleted Grants09/01/18-08/31/19(PI, 18.75%)“Evaluation of host targeted Monoclonal antibody in SARS-CoV Model”Regeneron, Inc.Total Direct Costs: $103,239Total Costs: $159,904 09/01/18-08/31/19(PI, 18.75%)“Evaluation of Anti-MERS Spike Monoclonal antibody in MERS-CoV Model”Regeneron, Inc.Total Direct Costs: $108,239Total Costs: $167,229 08/01/18-07/21/19(PI, 7.5%)“Nucleoside Analogues as Coronavirus Anti-viral Therapeutics”Alios/Jannsen/Johnson and JohnsonTotal Direct Costs: $163,770Total Costs: $241,560 01/17/18-01/16/20(PI, 18.75%)“Yeast-based Screening Platform to Identify Anti-Viral Compounds and Novel Targets for Respiratory Syncytial Virus (RSV) and Human Norovirus (NV)”Emergent BioSolutions, Inc.Annual Direct Costs: $275,112 Total Direct Costs: $550,224 Total Costs: $811,58210/01/2017-09/30/19(PI, 5%)Fluoroquinolone Testing against Emerging CoronavirusesEmergent BioSolutions, IncTotal Direct Costs: $33,712Total Cost: $49,72608/01/18-07/21/19(PI, 7.5%)“Nucleoside Analogues as Coronavirus Anti-viral Therapeutics”Alios/Jannsen/Johnson and JohnsonTotal Direct Costs: $163,770Total Costs: $241,560 11/27/16-09/10/18(Co-Inv, 30%, D. Milton, UMCP)“Contagious Phenotypes of Acute Respiratory Infection: Identification, Characterization, and Biomarkers”University of Maryland College Park / DARPA / Award #49887Total Direct Costs: $79,003Total Costs: $121,66508/14/17-08/13/18(Co-Inv, 17%; PI: D. Milton, UMCP)“Contagious Phenotypes of Acute Respiratory Infection: Identification, Characterization, and Biomarkers”University of Maryland College Park / DARPA / 58343-Z9127201Total Direct Costs: $28,850Total Costs: $44,573-The goal is to identify the patterns of respiratory virus transmission in freshman dorms at U of MD College Park. I helped establish a respiratory virus testing platform for use in the detection of viruses in students. In addition, we will aid in the sequencing of selected virus samples to follow virus changes during transmission.07/01/17-08/31/18(Co-PI with Dr. Colleen Burge (UMBC))“Development of Primary and Immortalized Cell Lines to Study Host Susceptibility to the Ostreid herpesvirus 1” UMB-UMBC Partnership Grant ProgramTotal Direct Costs: $25,000Total Costs: $25,000-The goal is to develop immortalized cell lines for Oysters for the study of Oyster herpesvirus06/13/16-05/31/18 (PI, 30%)“Diabetic Comorbidity and MERS Coronavirus Pathogenesis”NIAID/NIH R21 AI126300-01Total Direct Costs: $275,000Total Costs: $428,718 02/17/17-09/30/17(Consortium PI, 10%; PI: K. Wycoff)“A mucosally targeted MERS-CoV vaccine produced in plants”Planet Biotechnology, Inc.Total Direct Costs: $45,572Total Costs: $70,181-The goal of this project is to develop a MERS-CoV vaccine via plant based expression of the Spike protein. Our role is to aid in the development of the expression construct, determine the role of glycosylation on the Spike protein as it pertains to vaccine immunogenicity and perform vaccine experiments in mice with MERS-CoV.04/06/16-04/05/17(PI, 25%)“In vivo testing of Novavax MERS-CoV Spike Nanoparticle Vaccine”NovavaxTotal Direct Costs: $38,216Total Costs: $56,36909/15/15-07/31/17(Co-Inv, 25%; PI: K. Wycoff) “A MERS Decoy Receptor”NIH/NIAID SBIR Phase II / Planet Biotechnology / R44 AI114023Total Direct Costs $124,439Total Direct Costs: $248,878-The goal of this project is to develop an inhibitor of MERS-CoV replication in vitro and in vivo. We 10/20/15-10/19/16(PI, 8.3% effort)“Testing of BCX4430”Biocryst Pharmaceuticals, Inc.Total Direct Costs: $33,822Total Costs: $49,88707/01/11-06/30/17 (PI, 20%)“Role of the Epithelial Growth Factor Receptor in SARS Coronavirus Pathogenesis”NIAID/NIH RO1AI 095569-01Total Direct Costs: $1,500,937Total Costs: $2,260,60912/01/14-05/31/15 (PI, 15%)“Testing of Nitaxozanide in a mouse model of MERS-COV”Romark LaboratoriesTotal Direct Costs: $16,950Total Costs: $25,000 08/25/14-08/24/15 (PI, 15%)“In vitro and in vivo testing of MERS spike Antibodies”Regeneron, IncTotal Direct Costs: $140,798Total Costs: $207,677 (total costs)02/06/14-02/05/17 (PI, 10% effort)“Testing SARS and MERS Antiviral compounds” Unither Virology, LLCAnnual Direct Costs: $18,108.47Total Direct Costs: $54,325.41Total Costs: $80,130 09/06/13-10/31/15(Co-PI, 5%)“Whole Genome Approach to Microbial Forensics”J. Craig Venter Institute / JCVI-13-009Total Direct Costs: $57,387Total Costs: $88,09005/01/12-04/30/14(Co-PI, 20% effort) PI: Thomas Morrison, University of Colorado “Identification of Anti-viral compounds against Chikungunya Virus”Rocky Mountain Research Center of Excellence (RMRCE) Developmental grantNIH/NIAIDTotal Direct Costs: $102,768 Total Costs: $157,74809/12/10-09/30/12(Co-PI, 20% effort)PI: Dr. Eric Donaldson at U of N. Carolina, Chapel Hill“Metagenomic analysis of the virome of Eastern N. American Bats”Southeast Research Center of Excellence Developmental GrantNIH/NIAIDAnnual Direct Costs: $32,150 Total Annual Direct Costs: $64,300Total Costs: $96,45007/01/09-06/31/11 (PI, 50% effort)“SARS Coronavirus accessory proteins modulate the innate immune response”K22, NIH/NIAID Research Scholar Development Award Annual Direct Costs: 150,000Total Direct Costs: $250,000 PatentsOctober 2018Provisional Patent on “Nano3D printing enabled Microfluidic Platform for Virus Detection”February 2017“Methods of Treating Coronavirus Infections” US Patent #2017/0027975May 2014Provisional patent on “Treatment of Chikungunya virus with Fluoroquinolones”PublicationsPeer reviewed Journal Articles1.Frieman MB, Chen ZJ, Saez-Vasquez J, Shen LA, Pikaard CS. 1999. RNA polymerase I transcription in a Brassica interspecific hybrid and its progenitors: Tests of transcription factor involvement in nucleolar dominance. Genetics 152:451-460.2.Frieman MB, McCaffery JM, Cormack BP. 2002. Modular domain structure in the Candida glabrata adhesin Epa1p, a beta1,6 glucan-cross-linked cell wall protein. Mol Microbiol 46:479-492.3.Strichman-Almashanu LZ, Lee RS, Onyango PO, Perlman E, Flam F, Frieman MB, Feinberg AP. 2002. A genome-wide screen for normally methylated human CpG islands that can identify novel imprinted genes. Genome Res 12:543-554.4.Frieman MB, Cormack BP. 2003. The omega-site sequence of glycosylphosphatidylinositol-anchored proteins in Saccharomyces cerevisiae can determine distribution between the membrane and the cell wall. Mol Microbiol 50:883-896.5.Frieman MB, Cormack BP. 2004. Multiple sequence signals determine the distribution of glycosylphosphatidylinositol proteins between the plasma membrane and cell wall in Saccharomyces cerevisiae. Microbiology 150:3105-3114.6.Yount B, Roberts RS, Sims AC, Deming D, Frieman MB, Sparks J, Denison MR, Davis N, Baric RS. 2005. Severe acute respiratory syndrome coronavirus group-specific open reading frames encode nonessential functions for replication in cell cultures and mice. J Virol 79:14909-14922.7.Baric RS, Sheahan T, Deming D, Donaldson E, Yount B, Sims AC, Roberts RS, Frieman MB, Rockx B. 2006. SARS coronavirus vaccine development. Adv Exp Med Biol 581:553-560.8.Frieman MB, Yount B, Sims AC, Deming DJ, Morrison TE, Sparks J, Denison M, Heise M, Baric RS. 2006. SARS coronavirus accessory ORFs encode luxury functions. Adv Exp Med Biol 581:149-152.9.Frieman MB, Yount B, Heise M, Kopecky-Bromberg SA, Palese P, Baric RS. 2007. Severe acute respiratory syndrome coronavirus ORF6 antagonizes STAT1 function by sequestering nuclear import factors on the rough endoplasmic reticulum/Golgi membrane. J Virol 81:9812-9824.10.Kopecky-Bromberg SA, Martinez-Sobrido L, Frieman MB, Baric RA, Palese P. 2007. Severe acute respiratory syndrome coronavirus open reading frame (ORF) 3b, ORF 6, and nucleocapsid proteins function as interferon antagonists. J Virol 81:548-557.11.Wathelet MG, Orr M, Frieman MB, Baric RS. 2007. Severe acute respiratory syndrome coronavirus evades antiviral signaling: role of nsp1 and rational design of an attenuated strain. J Virol 81:11620-11633.12.Frieman MB, Baric R. 2008. Mechanisms of severe acute respiratory syndrome pathogenesis and innate immunomodulation. Microbiol Mol Biol Rev 72:672-685, Table of Contents.13.Frieman MB, Heise M, Baric R. 2008. SARS coronavirus and innate immunity. Virus Res 133:101-112.14.Zupancic ML, Frieman MB, Smith D, Alvarez RA, Cummings RD, Cormack BP. 2008. Glycan microarray analysis of Candida glabrata adhesin ligand specificity. Mol Microbiol 68:547-559.15.Rockx B, Baas T, Zornetzer GA, Haagmans B, Sheahan T, Frieman MB, Dyer MD, Teal TH, Proll S, van den Brand J, Baric R, Katze MG. 2009. Early upregulation of acute respiratory distress syndrome-associated cytokines promotes lethal disease in an aged-mouse model of severe acute respiratory syndrome coronavirus infection. J Virol 83:7062-7074.16.Frieman MB, Ratia K, Johnston RE, Mesecar AD, Baric RS. 2009. Severe acute respiratory syndrome coronavirus papain-like protease ubiquitin-like domain and catalytic domain regulate antagonism of IRF3 and NF-kappaB signaling. J Virol 83:6689-6705.17.Day CW, Baric R, Cai SX, Frieman MB, Kumaki Y, Morrey JD, Smee DF, Barnard DL. 2009. A new mouse-adapted strain of SARS-CoV as a lethal model for evaluating antiviral agents in vitro and in vivo. Virology 395:210-222.18.Basu D, Walkiewicz MP, Frieman MB, Baric RS, Auble DT, Engel DA. 2009. Novel influenza virus NS1 antagonists block replication and restore innate immune function. J Virol 83:1881-1891.19.Donaldson EF, Haskew AN, Gates JE, Huynh J, Moore CJ, Frieman MB. 2010. Metagenomic analysis of the viromes of three North American bat species: viral diversity among different bat species that share a common habitat. J Virol 84:13004-13018.20.Freundt EC, Yu L, Goldsmith CS, Welsh S, Cheng A, Yount B, Liu W, Frieman MB, Buchholz UJ, Screaton GR, Lippincott-Schwartz J, Zaki SR, Xu XN, Baric RS, Subbarao K, Lenardo MJ. 2010. The open reading frame 3a protein of severe acute respiratory syndrome-associated coronavirus promotes membrane rearrangement and cell death. J Virol 84:1097-1109.21.Frieman MB, Chen J, Morrison TE, Whitmore A, Funkhouser W, Ward JM, Lamirande EW, Roberts A, Heise M, Subbarao K, Baric RS. 2010. SARS-CoV pathogenesis is regulated by a STAT1 dependent but a type I, II and III interferon receptor independent mechanism. PLoS Pathog 6:e1000849.22.Peng X, Gralinski L, Armour CD, Ferris MT, Thomas MJ, Proll S, Bradel-Tretheway BG, Korth MJ, Castle JC, Biery MC, Bouzek HK, Haynor DR, Frieman MB, Heise M, Raymond CK, Baric RS, Katze MG. 2010. Unique signatures of long noncoding RNA expression in response to virus infection and altered innate immune signaling. MBio 1.23.Rockx B, Donaldson E, Frieman MB, Sheahan T, Corti D, Lanzavecchia A, Baric RS. 2010. Escape from human monoclonal antibody neutralization affects in vitro and in vivo fitness of severe acute respiratory syndrome coronavirus. J Infect Dis 201:946-955.24.Zornetzer GA, Frieman MB, Rosenzweig E, Korth MJ, Page C, Baric RS, Katze MG. 2010. Transcriptomic analysis reveals a mechanism for a prefibrotic phenotype in STAT1 knockout mice during severe acute respiratory syndrome coronavirus infection. J Virol 84:11297-11309.25.Peng X, Gralinski L, Ferris MT, Frieman MB, Thomas MJ, Proll S, Korth MJ, Tisoncik JR, Heise M, Luo S, Schroth GP, Tumpey TM, Li C, Kawaoka Y, Baric RS, Katze MG. 2011. Integrative deep sequencing of the mouse lung transcriptome reveals differential expression of diverse classes of small RNAs in response to respiratory virus infection. MBio 2.26.Frieman MB, Basu D, Matthews K, Taylor J, Jones G, Pickles R, Baric R, Engel DA. 2011. Yeast based small molecule screen for inhibitors of SARS-CoV. PLoS One 6:e28479.27.Aylor DL, Valdar W, Foulds-Mathes W, Buus RJ, Verdugo RA, Baric RS, Ferris MT, Frelinger JA, Heise M, Frieman MB, Gralinski LE, Bell TA, Didion JD, Hua K, Nehrenberg DL, Powell CL, Steigerwalt J, Xie Y, Kelada SN, Collins FS, Yang IV, Schwartz DA, Branstetter LA, Chesler EJ, Miller DR, Spence J, Liu EY, McMillan L, Sarkar A, Wang J, Wang W, Zhang Q, Broman KW, Korstanje R, Durrant C, Mott R, Iraqi FA, Pomp D, Threadgill D, de Villena FP, Churchill GA. 2011. Genetic analysis of complex traits in the emerging Collaborative Cross. Genome Res 21:1213-1222.28.Chen WH, Toapanta FR, Shirey KA, Zhang L, Giannelou A, Page C, Frieman MB, Vogel SN, Cross AS. 2012. Potential role for alternatively activated macrophages in the secondary bacterial infection during recovery from influenza. Immunol Lett 141:227-234.29.Frieman MB, Yount B, Agnihothram S, Page C, Donaldson E, Roberts A, Vogel L, Woodruff B, Scorpio D, Subbarao K, Baric RS. 2012. Molecular determinants of severe acute respiratory syndrome coronavirus pathogenesis and virulence in young and aged mouse models of human disease. J Virol 86:884-897.30.Huynh J, Li S, Yount B, Smith A, Sturges L, Olsen JC, Nagel J, Johnson JB, Agnihothram S, Gates JE, Frieman MB, Baric RS, Donaldson EF. 2012. Evidence supporting a zoonotic origin of human coronavirus strain NL63. J Virol 86:12816-12825.31.Page C, Goicochea L, Matthews K, Zhang Y, Klover P, Holtzman MJ, Hennighausen L, Frieman MB. 2012. Induction of alternatively activated macrophages enhances pathogenesis during severe acute respiratory syndrome coronavirus infection. J Virol 86:13334-13349.32.Coleman CM, Frieman MB. 2013. Emergence of the Middle East respiratory syndrome coronavirus. PLoS Pathog 9:e1003595.33.Adedeji AO, Singh K, Kassim A, Coleman CM, Elliott R, Weiss SR, Frieman MB, Sarafianos SG. 2014. Evaluation of SSYA10-001 as a replication inhibitor of severe acute respiratory syndrome, mouse hepatitis, and Middle East respiratory syndrome coronaviruses. Antimicrob Agents Chemother 58:4894-4898.34.Coleman CM, Frieman MB. 2014. Treating MERS-CoV during an outbreak. Lancet Infect Dis 14:1030-1031.35.Matthews KL, Coleman CM, van der Meer Y, Snijder EJ, Frieman MB. 2014. The ORF4b-encoded accessory proteins of Middle East respiratory syndrome coronavirus and two related bat coronaviruses localize to the nucleus and inhibit innate immune signalling. J Gen Virol 95:874-882.36.Matthews K, Schafer A, Pham A, Frieman MB. 2014. The SARS coronavirus papain like protease can inhibit IRF3 at a post activation step that requires deubiquitination activity. Virol J 11:209.37.Li J, Sun W, Subrahmanyam PB, Page C, Younger KM, Tiper IV, Frieman MB, Kimball AS, Webb TJ. 2014. NKT Cell Responses to B Cell Lymphoma. Med Sci (Basel) 2:82-97.38.Ladner JT, Beitzel B, Chain PS, Davenport MG, Donaldson EF, Frieman MB, Kugelman JR, Kuhn JH, O'Rear J, Sabeti PC, Wentworth DE, Wiley MR, Yu GY, Threat Characterization C, Sozhamannan S, Bradburne C, Palacios G. 2014. Standards for sequencing viral genomes in the era of high-throughput sequencing. MBio 5:e01360-01314.39.Kim WK, Jain D, Sanchez MD, Koziol-White CJ, Matthews K, Ge MQ, Haczku A, Panettieri RA, Jr., Frieman MB, Lopez CB. 2014. Deficiency of melanoma differentiation-associated protein 5 results in exacerbated chronic postviral lung inflammation. Am J Respir Crit Care Med 189:437-448.40.Hart BJ, Dyall J, Postnikova E, Zhou H, Kindrachuk J, Johnson RF, Olinger GG, Jr., Frieman MB, Holbrook MR, Jahrling PB, Hensley L. 2014. Interferon-beta and mycophenolic acid are potent inhibitors of Middle East respiratory syndrome coronavirus in cell-based assays. J Gen Virol 95:571-577.41.Frieman MB. 2014. The art of war: battles between virus and host. Curr Opin Virol 6:76-77.42.Enjuanes L, Sola I, Frieman MB. 2014. Virus Research. Nidoviruses I. Foreword. Virus Res 194:1-2.43.Dyall J, Coleman CM, Hart BJ, Venkataraman T, Holbrook MR, Kindrachuk J, Johnson RF, Olinger GG, Jr., Jahrling PB, Laidlaw M, Johansen LM, Lear-Rooney CM, Glass PJ, Hensley LE, Frieman MB. 2014. Repurposing of clinically developed drugs for treatment of Middle East respiratory syndrome coronavirus infection. Antimicrob Agents Chemother 58:4885-4893.44.Coleman CM, Matthews KL, Goicochea L, Frieman MB. 2014. Wild-type and innate immune-deficient mice are not susceptible to the Middle East respiratory syndrome coronavirus. J Gen Virol 95:408-412.45.Coleman CM, Liu YV, Mu H, Taylor JK, Massare M, Flyer DC, Smith GE, Frieman MB. 2014. Purified coronavirus spike protein nanoparticles induce coronavirus neutralizing antibodies in mice. Vaccine 32:3169-3174.46.Coleman CM, Frieman MB. 2014. Coronaviruses: important emerging human pathogens. J Virol 88:5209-5212.47.Taylor JK, Coleman CM, Postel S, Sisk JM, Bernbaum JG, Venkataraman T, Sundberg EJ, Frieman MB. 2015. Severe Acute Respiratory Syndrome Coronavirus ORF7a Inhibits Bone Marrow Stromal Antigen 2 Virion Tethering through a Novel Mechanism of Glycosylation Interference. J Virol 89:11820-11833.48.Sisk JM, Frieman MB. 2015. Screening of FDA-Approved Drugs for Treatment of Emerging Pathogens. ACS Infect Dis 1:401-402.49.Pascal KE, Coleman CM, Mujica AO, Kamat V, Badithe A, Fairhurst J, Hunt C, Strein J, Berrebi A, Sisk JM, Matthews KL, Babb R, Chen G, Lai KM, Huang TT, Olson W, Yancopoulos GD, Stahl N, Frieman MB*, Kyratsous CA*. 2015. Pre- and postexposure efficacy of fully human antibodies against Spike protein in a novel humanized mouse model of MERS-CoV infection. Proc Natl Acad Sci U S A 112:8738-8743.50.Nita-Lazar M, Banerjee A, Feng C, Amin MN, Frieman MB, Chen WH, Cross AS, Wang LX, Vasta GR. 2015. Desialylation of airway epithelial cells during influenza virus infection enhances pneumococcal adhesion via galectin binding. Mol Immunol 65:1-16.51.Mojica SA, Hovis KM, Frieman MB, Tran B, Hsia RC, Ravel J, Jenkins-Houk C, Wilson KL, Bavoil PM. 2015. SINC, a type III secreted protein of Chlamydia psittaci, targets the inner nuclear membrane of infected cells and uninfected neighbors. Mol Biol Cell 26:1918-1934.52.McSweegan E, Weaver SC, Lecuit M, Frieman MB, Morrison TE, Hrynkow S. 2015. The Global Virus Network: Challenging chikungunya. Antiviral Res 120:147-152.53.Kindrachuk J, Ork B, Hart BJ, Mazur S, Holbrook MR, Frieman MB, Traynor D, Johnson RF, Dyall J, Kuhn JH, Olinger GG, Hensley LE, Jahrling PB. 2015. Antiviral potential of ERK/MAPK and PI3K/AKT/mTOR signaling modulation for Middle East respiratory syndrome coronavirus infection as identified by temporal kinome analysis. Antimicrob Agents Chemother 59:1088-1099.54.Gralinski LE, Ferris MT, Aylor DL, Whitmore AC, Green R, Frieman MB, Deming D, Menachery VD, Miller DR, Buus RJ, Bell TA, Churchill GA, Threadgill DW, Katze MG, McMillan L, Valdar W, Heise MT, Pardo-Manuel de Villena F, Baric RS. 2015. Genome Wide Identification of SARS-CoV Susceptibility Loci Using the Collaborative Cross. PLoS Genet 11:e1005504.55.Frieman MB, Sola I, Enjuanes L. 2015. Virus Research. Foreword. Nidoviruses II. Virus Res 202:1-2.56.Coleman CM, Frieman MB. 2015. Growth and Quantification of MERS-CoV Infection. Curr Protoc Microbiol 37:15E 12 11-19.57.Astry B, Venkatesha SH, Laurence A, Christensen-Quick A, Garzino-Demo A, Frieman MB, O'Shea JJ, Moudgil KD. 2015. Celastrol, a Chinese herbal compound, controls autoimmune inflammation by altering the balance of pathogenic and regulatory T cells in the target organ. Clin Immunol 157:228-238.58.Coleman CM, Sisk JM, Mingo RM, Nelson EA, White JM, Frieman MB. 2016. Abelson Kinase Inhibitors Are Potent Inhibitors of Severe Acute Respiratory Syndrome Coronavirus and Middle East Respiratory Syndrome Coronavirus Fusion. J Virol 90:8924-8933.59.Luke T, Wu H, Zhao J, Channappanavar R, Coleman CM, Jiao JA, Matsushita H, Liu Y, Postnikova EN, Ork BL, Glenn G, Flyer D, Defang G, Raviprakash K, Kochel T, Wang J, Nie W, Smith G, Hensley LE, Olinger GG, Kuhn JH, Holbrook MR, Johnson RF, Perlman S, Sullivan E, Frieman MB. 2016. Human polyclonal immunoglobulin G from transchromosomic bovines inhibits MERS-CoV in vivo. Sci Transl Med 8:326ra321.60.Moser LA, Ramirez-Carvajal L, Puri V, Pauszek SJ, Matthews K, Dilley KA, Mullan C, McGraw J, Khayat M, Beeri K, Yee A, Dugan V, Heise MT, Frieman MB, Rodriguez LL, Bernard KA, Wentworth DE, Stockwell TB, Shabman RS. 2016. A Universal Next-Generation Sequencing Protocol To Generate Noninfectious Barcoded cDNA Libraries from High-Containment RNA Viruses. mSystems 1.61.Wirblich C, Coleman CM, Kurup D, Abraham TS, Bernbaum JG, Jahrling PB, Hensley LE, Johnson RF, Frieman MB, Schnell MJ. 2017. One-Health: a Safe, Efficient, Dual-Use Vaccine for Humans and Animals against Middle East Respiratory Syndrome Coronavirus and Rabies Virus. J Virol 91.62.Venkataraman T, Frieman MB. 2017. The role of epidermal growth factor receptor (EGFR) signaling in SARS coronavirus-induced pulmonary fibrosis. Antiviral Res 143:142-150.63.Venkataraman T, Coleman CM, Frieman MB. Overactive Epidermal Growth Factor Receptor Signaling Leads to Increased Fibrosis after Severe Acute Respiratory Syndrome Coronavirus Infection. J Virol. 2017 May 26;91(12). pii: e00182-17. doi:10.1128/JVI.00182-17. Print 2017 Jun 15. PubMed PMID: 28404843; PubMed Central PMCID: PMC5446658.64.Dyall J, Gross R, Kindrachuk J, Johnson RF, Olinger GG, Jr., Hensley LE, Frieman MB, Jahrling PB. 2017. Middle East Respiratory Syndrome and Severe Acute Respiratory Syndrome: Current Therapeutic Options and Potential Targets for Novel Therapies. Drugs 77:1935-1966.65.Coleman CM, Venkataraman T, Liu YV, Glenn GM, Smith GE, Flyer DC, Frieman MB. 2017. MERS-CoV spike nanoparticles protect mice from MERS-CoV infection. Vaccine 35:1586-1589.66.Coleman CM, Sisk JM, Halasz G, Zhong J, Beck SE, Matthews KL, Venkataraman T, Rajagopalan S, Kyratsous CA, Frieman MB. CD8+ T Cells and Macrophages Regulate Pathogenesis in a Mouse Model of Middle East Respiratory Syndrome. J Virol. 2016 Dec 16;91(1). pii: e01825-16.67.Cong Y, Hart BJ, Gross R, Zhou H, Frieman MB, Bollinger L, Wada J, Hensley LE, Jahrling PB, Dyall J, Holbrook MR. 2018. MERS-CoV pathogenesis and antiviral efficacy of licensed drugs in human monocyte-derived antigen-presenting cells. PLoS One 13:e0194868.68.Rao X, Deiuliis JA, Mihai G, Varghese J, Xia C, Frieman MB, Sztalryd C, Sun XJ, Quon MJ, Taylor SI, Rajagopalan S, Zhong J. 2018. Monocyte DPP4 Expression in Human Atherosclerosis Is Associated With Obesity and Dyslipidemia. Diabetes Care 41:e1-e3.69.Sisk JM, Frieman MB, Machamer CE. 2018. Coronavirus S protein-induced fusion is blocked prior to hemifusion by Abl kinase inhibitors. J Gen Virol 99:619-630.70.Banerjee A, Kulcsar K, Misra V,?Frieman M, Mossman K. 2019. Bats and Coronaviruses.?Viruses. 11.71. Weston S, Matthews KL, Lent R, Vlk A, Haupt R, Kingsbury T, Frieman MB. AYeast Suppressor Screen Used To Identify Mammalian SIRT1 as a Proviral Factor for Middle East Respiratory Syndrome Coronavirus Replication. J Virol. 2019 Jul 30;93(16). pii: e00197-19. Print 2019 Aug 15. orbid diabetes results in immune dysregulation and enhanced disease severity following MERS-CoV infection. Kulcsar KA, Coleman CM, Beck SE, Frieman MB. JCI Insight. 2019 Oct 17;4(20):e131774. doi: 10.1172/jci.insight.131774. PMID: 3155024373. COVID-19: Knowns, Unknowns, and Questions. Weston S, Frieman MB. mSphere. 2020 Mar 18;5(2):e00203-20. doi: 10.1128/mSphere.00203-20. PMID: 32188753 74. Insights from nanomedicine into chloroquine efficacy against COVID-19. Hu TY, Frieman M, Wolfram J. Nat Nanotechnol. 2020 Mar 23:1-3. doi: 10.1038/s41565-020-0674-9. Online ahead of print. PMID: 32203437Major Invited SpeechesLocalFrieman, MB., SARS-CoV Coronavirus. MARCE BSL3 Training course. UMB. 2009.Frieman, MB., “Viruses”. Baltimore Port Discovery Elementary After-School Program. 2017.Frieman, MB., “Coronavirus Pathogenesis”. UMSOM Summer Scholars Seminar. 2018Frieman, MB., “Using yeast to identify host targets and therapeutics for viruses”. University of Maryland College Park, Virology Symposium. 2018.NationalFrieman, MB., “SARS-CoV encodes a virulence allele that interacts with host nuclear import”. 2006. American Society of Virology Meeting. Madison, WI.Frieman, MB., “SARS-CoV encodes a virulence allele that interacts with host nuclear import”. 2007. Plus Strand RNA Virus Meeting. Washington, DC.Frieman, MB., “SARS-CoV encodes a novel virulence factor that interacts with the nuclear import machinery”. 2007. American Society of Virology Meeting. Oregon State University, Corvallis, OR.Frieman, MB., “SARS-CoV PLP inhibits both IRF3 and NFkB signaling pathways”. 2008. 11th International Nidovirus Symposium.Frieman, MB., “SARS-CoV Pathogenesis”, Plus Strand RNA Virus Symposium. 2010. Atlanta, GA.Frieman, MB., “Role of STAT1 in SARS-CoV Pathogenesis”. 2010. American Society of Virology. Montana State University, Bozeman, MT.Frieman, MB., “Alternatively Activated Macrophages exacerbate SARS-CoV Pathogenesis”. 2011. American Society of Virology. Minneapolis, MN.Frieman, MB., “Induction of AAMs in exacerbation of SARS-CoV Pathogenesis”. Plus strand RNA virus meeting. Keystone, Colorado. 2012. Madison, WI.Frieman, MB., “Repurposing of FDA approved drugs as novel anti-virals for MERS-CoV and SARS-CoV”. 2013. Plus Strand RNA Virus Meeting. Boston, MA.Frieman, MB., “Repurposing of FDA approved drugs as novel anti-virals for MERS-CoV and SARS-CoV”. 2014. American Society of Virology. Colorado State University.Frieman, MB., “Alternatively activated macrophage induction contributes to SARS-CoV Pathogenesis”. 2014. American Society of Virology. Colorado State University.Frieman, MB., “MERS-CoV Pathogenesis”. 2015. ??Biomedical Advanced Research and Development Authority?(BARDA). Washington, DC.Frieman, MB., “MERS-CoV Nanoparticle Vaccine Efficacy”. 2015. ??Vaccine Congress. Washington DC.Frieman, MB., “MERS-CoV Model Development”. 2015. American Thoracic Society Annual Meeting. Denver, CO.Frieman, MB., “Development of Therapeutics against the Middle East Respiratory Syndrome Coronavirus. American Society of Microbiology Biodefense Meeting. 2015. Baltimore, MD.Frieman, MB., “ABL kinase inhibitors are potent inhibitors of SARS-CoV and MERS-CoV fusion” 2016. American Society of Virology. Virginia Tech, VA.Frieman, MB., “MERS-CoV Animal Model Development” 2016. NIH Conference on MERS-CoV Model Development.Frieman, MB., “ABL kinase inhibitors are potent inhibitors of SARS-CoV and MERS-CoV fusion” 2016. Keystone Meeting: Plus Strand RNA Virus Meeting. Austin, TXFrieman, MB., “MERS-CoV Pathogenesis and Therapeutic Development”. 2016. Gordon Research Conference on “Acute Lung Injury”. Galveston, TX.Frieman, MB., “MERS-CoV Pathogenesis and Therapeutic Development”. 2017. American Society of Virology. Madison, WI.Frieman, MB., “Emerging Viruses”. The Science and Entertainment Exchange/National Academy of Sciences. 2017. Woods Hole, MA.Frieman, MB., “Host Inflammatory Response during MERS-CoV Pathogenesis”. 2018. American Society of Virology. College Park, MD.Frieman, MB., “MERS-CoV Pathogenesis and Therapeutic Development”. 2018. Gordon Research Conference on “Acute Lung Injury”. Ventura, CA.InternationalFrieman, MB., “SARS-CoV pathogenesis is controlled via a STAT1 dependent but Type I or Type II Interferon independent mechanism”. 2008. 11th International Nidovirus Symposium. St. Catherine’s College Oxford, England.Frieman, MB., “Alternatively activated macrophage induction contributes to SARS-CoV Pathogenesis”. 2014. 12th International Nidovirus Meeting. Salamanca, Spain.Frieman, MB., “MERS-CoV Mouse Model Development and Therapeutic Development”. WHO meeting on MERS-CoV Therapeutic Evaluation. Geneva, Switzerland. 2015.Frieman, MB., “MERS-CoV Pathogenesis”. 2015. American Society of Virology. London, Ontario.Frieman, MB. “Rhabdovirus based MERS-CoV Vaccine Efficacy”. WHO meeting on MERS-CoV Therapeutic Evaluation. Geneva, Switzerland. 2015.Frieman, MB., “MERS-CoV Pathogenesis” Advancement in Scientific Understanding of Avian Influenza and MERS as Emerging Respiratory Threat to Public Health in Asia and Beyond- From Viral Evolution to Animal and Human Hosts. Beijing, China. 2015Frieman, MB., “MERS-CoV Mouse Model Development and Therapeutic Development”. Dasan Conference. Dasan, South Korea. 2015.Frieman, MB., “MERS Coronavirus Pathogenesis and Therapeutic Development”. Gordon Research Conference “Viruses and Cells”. Luca, Italy. 2017Invited Seminars other than Conferences “Innate Immune Antagonism Governs SARS-CoV Pathogenesis”. 2007. Loyola University, Chicago. Invited by Susan Baker.“Host factors regulating SARS-CoV Pathogenesis”. 2009. Johns Hopkins University School of Public Health. Invited by Andrew Pekocz.“SARS-CoV mechanisms of Pathogenesis”. Keynote for UMSOM Summer Research Training Symposium. Invited by UMSOM.“Emergence of MERS Coronavirus”. 2013. Life Technologies Inc, South San Francisco, CA. Invited by Jonathon Wang.“Emergence of MERS Coronavirus”. 2013. National Institute of Allergy and Infectious Diseases. Invited by Jonathon Yewdell.“Emergence of MERS Coronavirus”. 2013. University of Pittsburgh Medical Center, Center for Health Security. Invited by D.A. Henderson.“Emergence of MERS Coronavirus”. 2013. National Institutes of Health, Integrated Research Facility. Invited by Peter Jahrling.“MERS-CoV Mouse model development”. 2013. National Institutes of Health MERS Information Group. Invited by Anthony Fauci.“Host response regulates SARS-CoV Pathogenesis”. 2013. FDA. Invited by Mayra Garcia.“SARS-CoV and MERS-CoV Pathogenesis, How I got here”. 2013. Cellular and Molecular Medicine Graduate Program Alumni Seminar, Johns Hopkins University. Invited by Colleen Graham.“SARS-CoV and MERS-CoV Pathogenesis”. 2013. Chesapeake Area Biosafety Officers Meeting. Invited by Melissa Morland.“Repurposing of FDA approved drugs for MERS-CoV and SARS-CoV”. 2014. University of Texas Medical Branch, Galveston. Invited by Barry Rockx. “Detection and Pathogenesis of MERS Coronavirus”. 2014. Thermo Scientific, San Francisco, CA. Invited by Jonathon Wang.“MERS-CoV and SARS-CoV therapeutics and pathogenesis”. 2014. National Institutes of Health, Laboratory of Viral Diseases. Invited by Ted Pierson.“MERS-CoV therapeutics and pathogenesis”. 2014. Mt Sinai Medical Center, Invited by Matt Evans.“MERS-CoV therapeutics and pathogenesis”. 2014. NIH Office of Biodefense, Research Resources and Translational Research, Invited by John Bogdan.“Pathogenesis and Therapeutic Development for SARS-CoV and MERS-CoV”. 2015. University of Florida, Gainesville. Invited by Grant McFadden.“Pathogenesis and Therapeutic Development for SARS-CoV and MERS-CoV”. 2015. Boston University. Invited by Paul Duprex.“Therapeutic Development for MERS-CoV”. FDA Medical Countermeasures Initiative Hot Topics series. 2015. Invited by Robert Fischer.“MERS-CoV Pathogenesis and Therapeutic Development”. National Biodefense Analysis and Countermeasures Center. 2015. Invited by Victoria Jensen. “MERS-CoV Pathogenesis and Therapeutic Development”. 2016. Invited by Melissa Morland. Chesapeake Area Biosafety Officers Association.“Therapeutic Development for Emerging Coronaviruses”, Gordon Conference on Acute Respiratory Infections. March 2016.“Pathogenesis and Therapeutic Development for SARS-CoV and MERS-CoV”. 2016. UMB-IMET. Invited by Colleen Burge.“Pathogenesis and Therapeutic Development for SARS-CoV and MERS-CoV”. 2016. Gilead Pharmaceuticals, San Francisco, CA. Invited by Robert Jordan.“Pathogenesis and Therapeutic Development for SARS-CoV and MERS-CoV”. 2016. Vanderbilt University. Invited by Terry Dermody.“Identification and Characterization of ABL Kinase Inhibitors as Potent Inhibitors of SARS-CoV and MERS-CoV Fusion”, Keystone Conference on Plus Strand RNA Viruses. May 2016.“Zika Virus”. The Chip Kelley Show. WVON Radio, Chicago. 2016 “MERS-CoV Pathogenesis and Therapeutic Development”. 2017. Invited by Ann Simon. University of Maryland at College Park. “MERS-CoV Pathogenesis and Therapeutic Development”. 2018. Invited by Stacey Shultz-Cherry. St. Judes Childrens Hospital.“MERS-CoV Pathogenesis and Therapeutic Development”. 2018. Invited by Bernardo Maniou. Emory University.“MERS-CoV Pathogenesis and Therapeutic Development”. 2019. Invited by Joe Zeigelbauer. NIH/NIAID.“MERS-CoV Pathogenesis and Therapeutic Development”. 2019. Invited by Eric Freed. NIH National Cancer Institute.“MERS-CoV Pathogenesis and Therapeutic Development”. 2019. Invited by Elaine Youngman. Villanova University.“MERS-CoV Pathogenesis and Therapeutic Development”. 2019. Invited by Sanjay Vashee. J. Craig Venter Institute.Guest on This Week in Virology PodcastTWIV 65: Matt’s Bats (1/20/2010)TWIV 75: Rabies rampant (3/28/2010)TWIV 171: One is the loneliest number (2/19/2012)TWIV 175: More than one way to skin a virus (3/18/2012)TWIV 204: M m m m, My Corona (10/21/2012)TWIV 207: Silk Sheets and viral infidelity (11/18/2012)TWIV 239: Filterable camels (6/30/2013)TWIV 258: Hedging our Bats (11/20/2013)TWIV 287: A potentially pandemic podcast (6/1/2014)The Science and Entertainment ExchangeExternal science consulting for media projects with:Will Staples (writer)Ari Lubek and Ian Clark (3 Arts Entertainment)Andy Landen (writer)Matt Reeves and Matt Bomback (Planet of the Apes)Danielle Mooney (writer, Don’t Forget to Breathe)Sabir Pirzada (writer)Michael Narducci (producer)Scott Kennedy (documentary filmmaker)Kristi Korzec (writer, Madam Secretary)Jonathon Sethna (writer)Zoie Nagelhout (writer, Marvel Studios)Advising and MentoringHigh School and Undergraduate Student Mentoring2010Mentor for Jane Valenti (then an Undergraduate at Towson University) as a research intern during the school year2011Mentor for Steve Rees (then an Undergraduate at Saint Mary’s College of Maryland) as a research intern during the school year2015Mentor for Sarah Johnson (then an Undergraduate at Loyola University) as a research intern during the school year2015Mentor for Sydnie Taylor (Baltimore City High School Student) through the UMB Summer BioScience Internship Program2015Mentor for Jack Siglin (then an Undergraduate at University of Maryland College Park) through the Nathan Schnaper Summer Intern Program in Cancer Research2016Mentor for Hayley Scott (then an Undergraduate at Loyola University) through the Nathan Schnaper Summer Intern Program in Cancer Research2017Mentor for Rachel Lent (then an Undergraduate at Towson University) through the Nathan Schnaper Summer Intern Program in Cancer Research2017Mentor for Nate Houchens (High School Student) for summer research project2017-18Mentor for Kayla Rayford through the STAR-PREP Program2018Mentor for Emily Robinson (Undergraduate at University of Maryland College Park) through the Maryland Scholars Summer Program2018Mentor for Chloe Keller (Undergraduate at University of Maryland College Park) for an independent summer research project2019Mentor for Kaitlyn Zwerling (Undergraduate at Loyola University) through the Nathan Schnaper Summer Intern Program in Cancer ResearchBasic Science Graduate Student Mentoring 2009-2014Member of the thesis committees for Katie Howell – GPILS Program in Molecular Microbiology and Immunology at the University of Maryland Baltimore – Thesis Title: Analysis of the Molecular Mechanisms Controlling HIV-1 Capsid Assembly and Capsid's Potential as a Drug Target”. Graduated (June 2014).2009-2013Chair of the thesis committees for Carly Page – GPILS Program in Molecular Microbiology and Immunology at the University of Maryland Baltimore – Thesis Title: Role of Alternatively Activated Macrophages in SARS-CoV Pathogenesis - Graduated (May 2013).2010-2014Chair of the thesis committees for Justin Taylor – GPILS Program in Molecular Microbiology and Immunology at the University of Maryland Baltimore – Thesis Title: Tetherin is a restriction factor for SARS-CoV replication- Graduated (June 2014).2010-presentMember of the thesis committees for Sergio Mojica – GPILS Program in Molecular Microbiology and Immunology at the University of Maryland Baltimore – Thesis Title: A newly identified type-III secreted effector of Chlamydia psittaci targets the nuclear envelope late in development.2010-presentMember of the thesis committees for Aaron Christenson-Quick – GPILS Program in Molecular Microbiology and Immunology at the University of Maryland Baltimore – Thesis Title: Blunting the intracellular permissiveness of Th17 cells to HIV infection.2013-presentChair of the thesis committees for Thiagarajan Venkataraman – GPILS Program in Molecular Microbiology and Immunology at the University of Maryland Baltimore – Thesis Title: Role of EGFR in SARS-CoV Pathogenesis.2017-presentMember of the thesis committees for Angel Corona Velazquez – GPILS Program in Molecular Microbiology and Immunology at the University of Maryland Baltimore2017-presentMember of the thesis committees for Abby McGillvray – GPILS Program in Molecular Microbiology and Immunology at the University of Maryland Baltimore2017-presentMember of the thesis committees for Jeremy Ardanuy – GPILS Program in Molecular Microbiology and Immunology at the University of Maryland Baltimore2018-presentMember of the thesis committees for Michael Lee – GPILS Program in Molecular Microbiology and Immunology at the University of Maryland Baltimore2018-presentMember of the thesis committees for Mingli Zhao – University of Maryland Baltimore Country, Marine-Estuarine Environmental Sciences Graduate Program.Basic Science Postdoctoral Fellows Mentoring 2012-2017Dr. Christopher Coleman – “MERS Coronavirus Therapeutics and Pathogenesis”. Currently Assistant Professor at The University of Nottingham, UK.2014-2016Dr. Jeanne Sisk, PhD. -- “Therapeutics for SARS-CoV and MERS-CoV”. Currently Biologist at the FDA Office of New Animal Drug Evaluation in the Center for Veterinary Medicine.2016-2019Dr. Kirsten Kulcsar, PhD. – “Diabetic Comorbidity Exacerbates MERS-CoV Pathogenesis”2016-Dr. Stuart Weston, PhD. – “Yeast based Platform to Identify Novel Host Factors and Therapeutics for Respiratory Viruses” ................
................

In order to avoid copyright disputes, this page is only a partial summary.

Google Online Preview   Download